Alpha Tau Medical Gets FDA Green Light for Prostate Cancer Trial
Ticker: DRTSW · Form: 6-K · Filed: Dec 2, 2025 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA approval, clinical trial, medical technology, prostate cancer
TL;DR
FDA approves Alpha Tau Medical's trial for prostate cancer – big step for their tech!
AI Summary
Alpha Tau Medical Ltd. announced on December 2, 2025, that it has received FDA approval to begin a trial for patients with locally recurrent prostate cancer. This marks a significant step in the company's efforts to expand the use of its cancer treatment technology.
Why It Matters
This FDA approval allows Alpha Tau Medical to proceed with a clinical trial, potentially validating their technology for a new patient group and expanding market opportunities.
Risk Assessment
Risk Level: medium — While FDA approval for a trial is positive, the success of the trial and subsequent commercialization remain uncertain.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — The company filing the report and receiving FDA approval.
- FDA (company) — The regulatory body that granted approval for the trial.
- December 2, 2025 (date) — The date the press release announcing the FDA approval was issued.
- locally recurrent prostate cancer (medical_condition) — The specific condition for which the trial will be conducted.
FAQ
What is the specific purpose of the FDA-approved trial for Alpha Tau Medical?
The trial is for patients with locally recurrent prostate cancer.
When was the announcement of the FDA approval made?
The announcement was made on December 2, 2025.
What form did Alpha Tau Medical file with the SEC?
Alpha Tau Medical Ltd. filed a Form 6-K.
What is Alpha Tau Medical's primary business classification?
Alpha Tau Medical Ltd. is classified under SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].
Is the information in this Form 6-K considered 'filed' for Section 18 purposes?
No, the information in this Report on Form 6-K, including Exhibit 99.1, is being furnished and shall not be deemed 'filed' for the purposes of Section 18.
Filing Stats: 300 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-12-02 09:02:01
Filing Documents
- ea026791901-6k_alphatau.htm (6-K) — 13KB
- ea026791901ex99-1_alphatau.htm (EX-99.1) — 10KB
- 0001213900-25-116980.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: December 2, 2025 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3